Skip to main content
. 2022 Oct 18;44(4):47. doi: 10.1007/s40656-022-00532-9

Fig. 4.

Fig. 4

The simulation of FPRP for the field of drug repurposing for COVID-19 for π(0-0.3) and β(0.6,0.8,0.9,1)

HHS Vulnerability Disclosure